To include your compound in the COVID-19 Resource Center, submit it here.

Proposed changes to CFIUS rules would ensnare more Chinese-backed U.S. biotechs

A proposed regulation from the Department of Treasury could change what triggers CFIUS review of foreign investment in U.S.-based “critical technology” companies. The rule could increase mandatory filings for companies with investors from countries subject to extensive U.S. export controls, including China.

Under the proposed rule, the Committee on Foreign Investment in the United States would

Read the full 553 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers